David Neskey, MD, Otolaryngology (ENT), Charleston, SC, MUSC Health of Medical University of South Carolina

DavidMichaelNeskeyMD

Otolaryngology (ENT) Charleston, SC

Head & Neck Oncologic Surgery

Assistant Professor Medical University of South Carolina Department of Otolaryngology Division of Head and Neck Oncologic Surgery Department of Cell and Molecular Pharmacology

Dr. Neskey is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Neskey's full profile

Already have an account?

Education & Training

  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterFellowship, Head & Neck Surgery, 2011 - 2014
  • Jackson Memorial Hospital - Jackson Health System
    Jackson Memorial Hospital - Jackson Health SystemResidency, Otolaryngology, 2006 - 2011
  • Albany Medical College
    Albany Medical CollegeClass of 2006
  • Colby CollegeB.A., Biology, 1995 - 1999

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2014 - 2021
  • TX State Medical License
    TX State Medical License 2013 - 2015
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • Best Basic Science Poster 8th International Conference on Head & Neck Cancer, 2012
  • Resident Research Award 2009-2010
  • Distinction in Research 2005-2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma  
    Neskey DM, Klein JD, Hicks S, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, JAMA Otolaryngol Head Neck Surg, 9/26/2013
  • Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53  
    Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ, Mol Cancer Ther. Mol Cancer Ther, 9/1/2013
  • Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma  
    Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP, J Oral Pathol Med, 5/26/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Surgical Salvage for Recurrent Oral Cavity Squamous Cell Carcinoma.
    Neskey DM, Boerner RM, Ward AW, Roberts DB, Kuoni SM, Stoneking JN, Tyler MA, Alukual P, Hutcheson KA, Weber RS, Sturgis EM, Myers JN, Zafereo ME, 5th World Congress - IFNOS and AHNS, New York, NY, 7/26/2014
  • Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma.
    Neskey DM, Klein JD, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, American Head and Neck Society, Orlando, FL, 4/10/2013
  • MK-1775, A selective Wee1 kinase Inhibitor, Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Squamous Cell Carcinoma of the Head and Neck.
    Osman AA, Monroe M, Alves Ortega M, Neskey DM, Patel AA, Chuang HC, Mason L, Meyn RE Byers L, Katsonis P, Lichtarge O, Myers JN, American Academy of Cancer Research, Washington, DC, 4/6/2013
  • Join now to see all

Authored Content

  • Evaluating Adjuvant Therapy with Chemoradiation vs Radiation Alone for Patients with HPV-Negative N2a Head and Neck CancerAugust 2020

Press Mentions

  • Jessica Thaxton, PhD with MUSC’s Hollings Cancer Center Secures $3.4m to Look at Immunotherapy and Cell Stress
    Jessica Thaxton, PhD with MUSC’s Hollings Cancer Center Secures $3.4m to Look at Immunotherapy and Cell StressJuly 26, 2020 09:26
  • New Associate Directors at Hollings Cancer Center to Advance Cancer Immunology
    New Associate Directors at Hollings Cancer Center to Advance Cancer ImmunologyApril 26, 2020 09:26

Grant Support

  • Paul Calebresi Clinical and Translational Oncology Training ProgramNational Cancer Institute2014–Present

Professional Memberships

Hospital Affiliations